Affymax to receive development milestone payment from Takeda
Pharmaceutical Business Review
Peginesatide, indicated to treat anemia associated with chronic kidney disease (CKD) in adult patients on dialysis, was discovered by Affymax. If approved, peginesatide will be co-marketed by Affymax and Takeda in the US. Takeda has commercialization ...
Takeda Announces Acceptance of European Marketing Authorisation Application ...SYS-CON Media (press release)
Affymax to Receive $5 Million Milestone Payment for Acceptance of European ...Lifescience-online
Search in our News (press release)
PMLiVE -Zenopa
all 20 news articles »